LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Lista de Ações・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Fechado

SetorSaúde

522.72 1.55

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

505.41

Máximo

528.38

Indicadores-chave
By Trading Economics
Rendimento	-36M -94M
Vendas	-9.7M 311M
EPS	-1.38
Margem de lucro	-30.318
Funcionários	915
EBITDA	-43M -93M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+25.63% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-20M 12B
Abertura anterior	521.17
Fecho anterior	522.72

Sentimento de Notícias

By Acuity

22%

78%

41 / 344 Ranking em Healthcare

Madrigal Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

26 de mai. de 2026, 16:52 UTC

Notícias Principais

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 de mai. de 2026, 23:57 UTC

Ganhos

Sociedad Quimica 1Q Rev $1.76B >SQM

26 de mai. de 2026, 23:57 UTC

Ganhos

Sociedad Quimica 1Q EPS $1.28 >SQM

26 de mai. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 de mai. de 2026, 21:54 UTC

Ganhos

Webco Industries 3Q EPS $11.61 >WEBC

26 de mai. de 2026, 21:54 UTC

Ganhos

Webco Industries 3Q Sales $179.6M >WEBC

26 de mai. de 2026, 21:48 UTC

Conversa de Mercado

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 de mai. de 2026, 21:00 UTC

Conversa de Mercado

ESG Roundup: Market Talk

26 de mai. de 2026, 20:58 UTC

Aquisições, Fusões, Aquisições de Empresas

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

26 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

26 de mai. de 2026, 19:22 UTC

Conversa de Mercado

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 de mai. de 2026, 19:17 UTC

Conversa de Mercado

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 de mai. de 2026, 18:56 UTC

Conversa de Mercado

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 de mai. de 2026, 18:03 UTC

Conversa de Mercado

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 de mai. de 2026, 17:42 UTC

Conversa de Mercado

Grains Await Fresh Trading Catalyst -- Market Talk

26 de mai. de 2026, 17:33 UTC

Conversa de Mercado

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 de mai. de 2026, 17:21 UTC

Conversa de Mercado

Canada Faces a Labor Market Squeeze -- Market Talk

26 de mai. de 2026, 16:52 UTC

Conversa de Mercado

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 de mai. de 2026, 16:43 UTC

Conversa de Mercado

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 de mai. de 2026, 16:24 UTC

Conversa de Mercado

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 de mai. de 2026, 16:21 UTC

Conversa de Mercado

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Auto & Transport Roundup: Market Talk

26 de mai. de 2026, 16:16 UTC

Conversa de Mercado

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 de mai. de 2026, 16:01 UTC

Conversa de Mercado

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 de mai. de 2026, 15:21 UTC

Conversa de Mercado

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Comparação entre Pares

Variação de preço

Madrigal Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

25.63% parte superior

Previsão para 12 meses

Média 649.82 USD 25.63%

Máximo 964 USD

Mínimo 513.59 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Madrigal Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para Madrigal Pharmaceuticals Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

41 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.